Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome

Henry, Ronald J. W.; Morales, Álvaro; Cahill, Catherine M.

doi:10.1016/j.urology.2015.01.021

Cited by 32 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in the present study, anionic KT exhibited the higher penetrated amount than cationic LID. The ionized KT and LID, calculated from p K a values, are 99.98% and 67% at pH 7.4, respectively, although the difference in the ionization degree decreases at weakly acidic pH conditions on skin . We infer that KT is more likely to be ionized under given condition, being responsible for this observation.…”

Section: Discussionmentioning

confidence: 71%

“…KT is a potent nonsteroidal anti‐inflammatory drug and can be administrated into the body through oral, injectable, and transmucosal methods . LID is a local anesthetic that can be administrated by oral, topical, or injectable methods . RIS is widely used for clinical treatment of metabolic bone diseases (e.g., osteoporosis) as an inhibitor of osteoclast activity and generally administrated by oral route.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Electrodeless Reverse Electrodialysis Patches as an Ionic Power Source for Active Transdermal Drug Delivery

Kwon

Nam

Park

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

Reverse electrodialysis (RED) is one of the promising sustainable technologies generating electric power from the mixing energy of two different salt solutions. Most of the reports on the RED systems are focused on scale-up development and the improvement of maximum power density. However, regarding biocompatible and eco-friendly natures, the RED system also has a great potential use where low electrical power is necessary, in particular for skin-wearable biomedical devices. In this work, electronics-free RED patches are devised as an ionic power source for active transdermal drug delivery. The electrodeless RED patches generate reliable voltages, which are proportional to the number of ion-exchange membranes and salinity ratios, and successfully facilitate in vitro delivery of ionic drugs through mouse skin without involving any electronic component for the first time; 9, 20, and 36-fold increases with lidocaine, ketorolac, and risedronate, respectively. Indeed, by using an osteoporosis-induced mouse model, the RED patch delivery demonstrates powerful in vivo therapeutic effects against the diffusion-based topical administration. The new ionic power source can allow transport of various types of drugs in the transdermal route and, more importantly, can be used for the operation of other portable biomedical devices.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Electrodeless Reverse Electrodialysis Patches as an Ionic Power Source for Active Transdermal Drug Delivery

Kwon

Nam

Park

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Local administration of lidocaine, a therapeutic option for IC management (Henry et al , ), was evaluated, and comparable results with F16357 in amplitude and duration were obtained. In humans, intravesical instillations of lidocaine 2% may interrupt the self‐perpetuating neuro‐inflammatory cycle presented in IC (Henry et al , ). In the current experimental model, the comparable effects obtained with lidocaine and F16357 confirm the involvement of pain sensation in the modification of the voiding pattern.…”

Section: Discussionmentioning

confidence: 98%

F16357, a novel protease‐activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis

Monjotin

Gillespie

Farrié

et al. 2016

British J Pharmacology

View full text Add to dashboard Cite

Background and PurposeThe aims of the present study were to characterize the role of PAR1 in rat bladder under inflammatory conditions and determine whether a selective PAR1 antagonist, F16357, can prevent the pathophysiological symptoms of cyclophosphamide‐induced interstitial cystitis (IC).Experimental ApproachImmunohistochemistry, contractile activity in isolated bladder and urodynamics were determined before and after cyclophosphamide treatment. F16357 was administered intravesically during the acute phase of inflammation, and effects on PAR1 and PAR1‐related bladder contraction evaluated 24 h after cyclophosphamide injection. Urodynamics and associated voided volumes were recorded 7 and 24 h after cyclophosphamide.Key ResultsIn control conditions, PAR1 was present only in some umbrella cells. Cyclophosphamide disrupted the urothelium and expression of PAR1 by all remaining urothelial cells. After F16357 treatment, urothelial damage was absent and PAR1 immunoreactivity similar to control tissues. Thrombin and TFLLR‐NH2 induced bladder contractions. These were increased in inflammatory conditions and antagonized by F16357 in a concentration‐dependent manner. In telemetric experiments, furosemide increased urine production and voiding frequency for 60 min, 7 h after cyclophosphamide injection. Intravesical administration of F16357 blocked these changes with a return to a physiological profile; 24 h after cyclophosphamide, the volume of micturition was still lower with no increase in number of micturitions. F16357 30 μM reduced the number of micturitions and improved bladder capacity, but did not affect diuresis. Under similar experimental conditions, lidocaine 2% induced comparable effects.Conclusions and ImplicationsPAR1 is expressed in rat bladder, overactivated in inflammatory conditions and involved in bladder function and sensation. F16357 could represent an interesting candidate for IC treatment.

show abstract

“…Local anesthetics also induce vasodilatation, reduce a pathologically increased capillary permeability, have antimicrobial properties, and exhibit a sympatholytic effect …”

Section: Discussionmentioning

confidence: 99%

“…36,37 Local anesthetics also induce vasodilatation, reduce a pathologically increased capillary permeability, have antimicrobial properties, and exhibit a sympatholytic effect. 26,28,38,39,40 Empirically, the number of sessions is decided according to the patients' reply to treatment, changing from three to seven sessions. In current study, we applied five sessions to the patients, in order to standardize our protocol and achieve optimized results.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of peripheral lidocaine application (neural therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients

Tamam

Özdemir

Gedik

et al. 2017

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

Beyond a Simple Anesthetic Effect: Lidocaine in the Diagnosis and Treatment of Interstitial Cystitis/bladder Pain Syndrome

Cited by 32 publications

References 49 publications

Electrodeless Reverse Electrodialysis Patches as an Ionic Power Source for Active Transdermal Drug Delivery

Electrodeless Reverse Electrodialysis Patches as an Ionic Power Source for Active Transdermal Drug Delivery

F16357, a novel protease‐activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis

Efficacy of peripheral lidocaine application (neural therapy) in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients

Contact Info

Product

Resources

About